sulfadoxine-pyrimethamine / mefloquine — Competitive Intelligence Brief

sulfadoxine-pyrimethamine / mefloquine (sulfadoxine-pyrimethamine / mefloquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Infectious Diseases.

phase 3 Antimalarial Plasmodium falciparum Infectious Diseases Small molecule

Target snapshot

sulfadoxine-pyrimethamine / mefloquine (sulfadoxine-pyrimethamine / mefloquine) — Institut de Recherche pour le Developpement. Sulfadoxine-pyrimethamine is a combination of a sulfonamide antibiotic and a dihydrofolate reductase inhibitor, while mefloquine is a blood schizonticide.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sulfadoxine-pyrimethamine / mefloquine TARGET	sulfadoxine-pyrimethamine / mefloquine	Institut de Recherche pour le Developpement	phase 3	Antimalarial	Plasmodium falciparum
Artemether, Lumefantrine Drug Combination	Artemether, Lumefantrine Drug Combination	University of Yaounde 1	marketed	Antimalarial combination	Plasmodium falciparum heme and mitochondrial function
SP-IPTp	SP-IPTp	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum dihydrofolate reductase (sulfadoxine-pyrimethamine); hemozoin formation (piperaquine)
IPTp-DP	IPTp-DP	Kenya Medical Research Institute	marketed	Antimalarial combination therapy	Plasmodium falciparum (malaria parasite)
Artesunate plus Amodiaquine	Artesunate plus Amodiaquine	Bernhard Nocht Institute for Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis)
arthemether + lumefantrine	arthemether + lumefantrine	Sanofi	marketed	Antimalarial combination	Plasmodium falciparum heme detoxification pathway; artemisinin-derived endoperoxide bridge
Artesunate + Amodiaquine	Artesunate + Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination	Plasmodium falciparum hemoglobin metabolism and DNA synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

1. London School of Hygiene and Tropical Medicine · 6 drugs in this class
2. Sanofi · 3 drugs in this class
3. Epicentre · 2 drugs in this class
4. University of Oxford · 2 drugs in this class
5. · 2 drugs in this class
6. Frantz Viral Therapeutics, LLC · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Institut de Recherche pour le Developpement · 1 drug in this class
9. Centre de Recherche Médicale de Lambaréné · 1 drug in this class
10. GlaxoSmithKline · 1 drug in this class